1 results match your criteria: "University of Western Ontario Residency Program[Affiliation]"
Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
J Surg Oncol
December 2011
Schulich School of Medicine and Dentistry, University of Western Ontario Residency Program, London, Ontario, Canada.
Purpose: To investigate the role of intra-lesional interleukin-2 (IL-2) injection for treatment of in-transit melanoma metastases.
Methods: Consecutive patients with in-transit metastases were treated with intra-lesional IL-2 injections. Two independent observers evaluated response to treatment using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.